OncoMatch

OncoMatch/Clinical Trials/NCT06960707

Two Versus One Week Breast Radiotherapy (RT)

Is NCT06960707 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.

Phase 3RecruitingWeill Medical College of Cornell UniversityNCT06960707Data as of May 2026

This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Disease stage

Required: Stage PT1, PT2, PTIS (AJCC TNM)

pT1-2 breast cancer excised with negative margins; pTis excised with negative margins

Prior therapy

Must have received: segmental mastectomy

Women status post segmental mastectomy

Cannot have received: radiation therapy

Exception: ipsilateral breast only

Previous radiation therapy to the ipsilateral breast

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Brooklyn Methodist Hospital · New York, New York
  • New York Presbyterian Hospital · New York, New York
  • New York-Presbyterian Weill Cornell Medical College · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify